Virtu Financial LLC Buys Shares of 18,992 ADMA Biologics, Inc. (NASDAQ:ADMA)

Virtu Financial LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,992 shares of the biotechnology company’s stock, valued at approximately $326,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the third quarter worth about $31,000. National Bank of Canada FI acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $35,000. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the period. Vision Financial Markets LLC acquired a new position in ADMA Biologics in the fourth quarter valued at approximately $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the third quarter valued at approximately $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $20.28 on Friday. The company’s 50 day simple moving average is $17.05 and its 200-day simple moving average is $18.13. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The company has a market capitalization of $4.79 billion, a price-to-earnings ratio of 72.43 and a beta of 0.60.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.